2025-02-11 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AGEN |
Sell
All
|
-15.67% |
Assets Rebalanced
None
2025-02-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AGEN
Agenus Inc.
|
Buy |
4.08% |
-8.62% |
2025-01-22 |
The percentage of cash held in the portfolio is:
95.92%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| BLFS |
Sell
All
|
-7.77% |
Assets Rebalanced
None
2025-02-07 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AGEN
Agenus Inc.
|
Buy |
4.35% |
-2.35% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.04% |
-7.46% |
2025-01-30 |
The percentage of cash held in the portfolio is:
91.61%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ORGO |
Sell
All
|
6.61% |
Assets Rebalanced
None
2025-02-06 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.97% |
8.11% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.52% |
1.83% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.1% |
-5.58% |
2025-01-30 |
The percentage of cash held in the portfolio is:
86.41%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| MD |
Sell
All
|
-0.14% |
| MDXG |
Sell
All
|
-3.17% |
| NVRO |
Sell
All
|
18.4% |
| LGND |
Sell
All
|
6.37% |
| AXSM |
Sell
All
|
21.6% |
| CERS |
Sell
All
|
1.62% |
| DNLI |
Sell
All
|
9.72% |
| ATXS |
Sell
All
|
-2.31% |
| RGNX |
Sell
All
|
13.31% |
| ANIP |
Sell
All
|
5.76% |
Assets Rebalanced
None
2025-02-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.78% |
-0.64% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.67% |
-3.06% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.82% |
20.99% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.12% |
6.33% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.8% |
20.45% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.84% |
0.54% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.15% |
6.93% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.65% |
-3.47% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
5.45% |
13.31% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.99% |
3.61% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.85% |
4.5% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.1% |
-8.62% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.08% |
-6.96% |
2025-01-30 |
The percentage of cash held in the portfolio is:
35.7%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| NUTX |
Sell
All
|
52.16% |
| ACRS |
Sell
All
|
0.4% |
Assets Rebalanced
None
2025-02-04 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NUTX
Nutex Health Inc.
|
Buy |
7.5% |
53.16% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.7% |
-4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.87% |
-0.57% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.74% |
-3.17% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.75% |
17.45% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.1% |
4.06% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.61% |
14.59% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.76% |
-2.7% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
4.97% |
1.58% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.67% |
-4.62% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
5.15% |
5.11% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
5.01% |
2.4% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.83% |
2.4% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.18% |
-8.36% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.2% |
-5.94% |
2025-01-30 |
The percentage of cash held in the portfolio is:
23.94%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AXGN |
Sell
All
|
-1.81% |
| INSM |
Sell
All
|
12.98% |
| SIGA |
Sell
All
|
-9.55% |
Assets Rebalanced
None
2025-02-03 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AXGN
AxoGen, Inc.
|
Buy |
4.78% |
-0.22% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.32% |
11.1% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
7.14% |
48.84% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.76% |
-0.8% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.79% |
-0.14% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.73% |
-1.36% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.73% |
19.58% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.07% |
5.69% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.44% |
13.56% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.85% |
1.08% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.2% |
8.37% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.84% |
0.9% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
5.2% |
8.47% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.97% |
3.7% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
5.11% |
10.51% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.43% |
-0.78% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
3.55% |
-6.42% |
2025-01-23 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.22% |
-3.5% |
2025-01-30 |
The percentage of cash held in the portfolio is:
9.89%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CPRX |
Sell
All
|
-5.84% |
| TGTX |
Sell
All
|
-0.69% |
Assets Rebalanced
None
2025-01-30 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AXGN
AxoGen, Inc.
|
Buy |
4.8% |
0.33% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.42% |
13.16% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
6.7% |
39.94% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.52% |
-5.6% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.85% |
1.36% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.91% |
2.61% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.71% |
19.34% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.16% |
7.83% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.37% |
12.15% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
5.02% |
4.86% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.21% |
8.88% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.58% |
-4.24% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
4.84% |
1.08% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
5.02% |
4.95% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
5.27% |
14.11% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.2% |
-5.74% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
3.71% |
-2.03% |
2025-01-23 |
|
TGTX
TG Therapeutics, Inc.
|
Buy |
3.97% |
4.54% |
2025-01-28 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
4.36% |
0% |
2025-01-30 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
Buy |
4.36% |
0% |
2025-01-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| AORT |
Sell
All
|
3.27% |
Assets Rebalanced
None
2025-01-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AORT
Artivion, Inc.
|
Buy |
4.87% |
1.36% |
2025-01-09 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.72% |
-1.75% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.41% |
12.62% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
6.08% |
26.44% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.71% |
-2% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
5.04% |
4.86% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.75% |
-1.25% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.68% |
18.16% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.11% |
6.35% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.27% |
9.54% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
5.59% |
16.22% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.19% |
7.86% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.65% |
-3.21% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
4.96% |
3.09% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
5.14% |
6.84% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
5.21% |
12.31% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.21% |
-6.01% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
3.77% |
-0.78% |
2025-01-23 |
|
TGTX
TG Therapeutics, Inc.
|
Buy |
3.81% |
0% |
2025-01-28 |
The percentage of cash held in the portfolio is:
5.81%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ESPR |
Sell
All
|
-14.96% |
| VERU |
Sell
All
|
-24.39% |
Assets Rebalanced
None
2025-01-23 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AORT
Artivion, Inc.
|
Buy |
4.82% |
1.82% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.46% |
-5.98% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.9% |
3.51% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.39% |
13.81% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
5.64% |
19.09% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.93% |
4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.76% |
0.5% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.83% |
1.93% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.48% |
15.57% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
4.98% |
5.06% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
5.17% |
9.09% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.64% |
-2.16% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.14% |
8.42% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.56% |
-3.72% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
5% |
5.51% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.87% |
2.85% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.8% |
5.11% |
2025-01-17 |
|
VERU
Veru Inc.
|
Buy |
5.66% |
23.81% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.22% |
-4.44% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
3.75% |
0% |
2025-01-23 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| BLUE |
Sell
All
|
-20.97% |
Assets Rebalanced
None
2025-01-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
BLUE
bluebird bio, Inc.
|
Buy |
3.88% |
-17.94% |
2025-01-07 |
|
AORT
Artivion, Inc.
|
Buy |
4.94% |
4.5% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.35% |
-8.12% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.92% |
3.95% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.27% |
11.34% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
5.69% |
20.31% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.92% |
4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.73% |
0% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.9% |
3.63% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.22% |
10.38% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
5.04% |
6.42% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
4.86% |
2.59% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.73% |
0% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
5.07% |
7.16% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.6% |
-2.82% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
4.82% |
1.75% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.88% |
3.18% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.84% |
6.01% |
2025-01-17 |
|
VERU
Veru Inc.
|
Buy |
5.92% |
29.76% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
4.41% |
0% |
2025-01-22 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| TNDM |
Sell
All
|
-5.5% |
Assets Rebalanced
None
2025-01-17 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.91% |
0.47% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.07% |
-16.73% |
2025-01-07 |
|
AORT
Artivion, Inc.
|
Buy |
5.05% |
3.34% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.72% |
-3.42% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.93% |
0.99% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.15% |
5.54% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
5.78% |
18.31% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.9% |
0.4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.8% |
-1.64% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
5.03% |
2.95% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
5.18% |
6.13% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
4.92% |
0.73% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
4.88% |
-0.06% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.81% |
-1.62% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
4.92% |
0.79% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.86% |
-0.51% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
4.69% |
-3.9% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.97% |
1.68% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
4.71% |
0% |
2025-01-17 |
|
VERU
Veru Inc.
|
Buy |
4.71% |
0% |
2025-01-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| MDRX |
Sell
All
|
-6.56% |
Assets Rebalanced
None
2025-01-16 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.77% |
-3.76% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.14% |
-16.43% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.73% |
-4.51% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
4.93% |
-0.56% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.68% |
-5.56% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
5.09% |
2.63% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
5.05% |
1.84% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
5.07% |
2.16% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.98% |
0.4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
MDXG
MiMedx Group, Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
NVRO
Nevro Corp.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
4.96% |
0% |
2025-01-16 |
|
AXSM
Axsome Therapeutics, Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
CERS
Cerus Corporation
|
Buy |
4.96% |
0% |
2025-01-16 |
|
DNLI
Denali Therapeutics Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
ATXS
Astria Therapeutics, Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
RGNX
REGENXBIO Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
Buy |
4.96% |
0% |
2025-01-16 |
The percentage of cash held in the portfolio is:
6.96%
New Assets Added
- MD
- MDXG
- NVRO
- LGND
- AXSM
- CERS
- DNLI
- ATXS
- RGNX
- ANIP
Assets Removed
| Asset |
Action |
Perf % |
| ARDX |
Sell
All
|
0.19% |
Assets Rebalanced
None
2025-01-15 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.77% |
-4.19% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.02% |
-19.25% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.65% |
-6.67% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
4.89% |
-1.82% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
5.24% |
5.24% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.77% |
-4.27% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.98% |
-0.05% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
4.93% |
-0.93% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
4.98% |
0% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
4.98% |
0% |
2025-01-15 |
The percentage of cash held in the portfolio is:
51.8%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-14 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.79% |
-3.07% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.23% |
-14.42% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.81% |
-2.56% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
4.79% |
-2.94% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
5.44% |
10.11% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.81% |
-2.56% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
4.94% |
0% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
4.94% |
0% |
2025-01-14 |
The percentage of cash held in the portfolio is:
61.26%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.79% |
-3.63% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.23% |
-14.72% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.84% |
-2.46% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
4.91% |
-1.16% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
4.72% |
-5.06% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.97% |
0% |
2025-01-13 |
The percentage of cash held in the portfolio is:
71.54%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.96% |
0.36% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.21% |
-14.72% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.82% |
-2.46% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
4.94% |
0% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
4.94% |
0% |
2025-01-09 |
The percentage of cash held in the portfolio is:
76.12%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.88% |
-0.82% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.48% |
-9.07% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
4.92% |
0% |
2025-01-08 |
The percentage of cash held in the portfolio is:
85.71%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
4.9% |
0% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
4.9% |
0% |
2025-01-07 |
The percentage of cash held in the portfolio is:
90.2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-12-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| PCRX |
Sell
All
|
NA |
Assets Rebalanced
None
2024-12-18 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
5.18% |
3.88% |
2024-12-05 |
The percentage of cash held in the portfolio is:
94.82%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| APLS |
Sell
All
|
5.82% |
| MGNX |
Sell
All
|
-1.76% |
Assets Rebalanced
None
2024-12-12 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
5.11% |
4.2% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
4.92% |
0.29% |
2024-11-27 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
5.3% |
6.5% |
2024-12-05 |
The percentage of cash held in the portfolio is:
84.66%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ESPR |
Sell
All
|
-13.23% |
Assets Rebalanced
None
2024-12-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
5.18% |
7.32% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
4.94% |
2.35% |
2024-11-27 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
6.09% |
23.55% |
2024-12-03 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
4.89% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
78.91%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| RVNC |
Sell
All
|
-27.34% |
Assets Rebalanced
None
2024-12-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
5% |
4.6% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
4.9% |
2.65% |
2024-11-27 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
5.76% |
18.06% |
2024-12-03 |
|
RVNC
Revance Therapeutics, Inc.
|
Buy |
4.84% |
0% |
2024-12-05 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
4.84% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
74.65%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARWR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-12-03 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
5.18% |
8.55% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
5.18% |
8.53% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
4.8% |
0.73% |
2024-11-28 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
4.87% |
0% |
2024-12-03 |
The percentage of cash held in the portfolio is:
79.97%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| FATE |
Sell
All
|
-6.62% |
Assets Rebalanced
None
2024-12-02 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
4.96% |
3.98% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
5.04% |
5.59% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
4.75% |
-0.46% |
2024-11-28 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
4.77% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
80.47%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ITGR |
Sell
All
|
2.73% |
Assets Rebalanced
None
2024-11-29 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ITGR
Integer Holdings Corporation
|
Buy |
4.41% |
2.95% |
2024-11-11 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
4.99% |
4.63% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
5.1% |
7.06% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
4.77% |
0% |
2024-11-28 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
4.77% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
75.97%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CHRS |
Sell
All
|
NA |
Assets Rebalanced
None
2024-11-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CHRS
Coherus BioSciences, Inc.
|
Buy |
7.24% |
53.66% |
2024-11-08 |
|
ITGR
Integer Holdings Corporation
|
Buy |
4.41% |
2.95% |
2024-11-11 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
4.99% |
4.63% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
5.1% |
7.06% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
4.77% |
0% |
2024-11-28 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
4.77% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
68.73%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CHRS
Coherus BioSciences, Inc.
|
Buy |
7.4% |
56.1% |
2024-11-08 |
|
ITGR
Integer Holdings Corporation
|
Buy |
4.37% |
1.48% |
2024-11-11 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
4.79% |
0% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
4.79% |
0% |
2024-11-27 |
The percentage of cash held in the portfolio is:
78.66%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-26 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CHRS
Coherus BioSciences, Inc.
|
Buy |
7.02% |
47.56% |
2024-11-08 |
|
ITGR
Integer Holdings Corporation
|
Buy |
4.43% |
2.57% |
2024-11-11 |
The percentage of cash held in the portfolio is:
88.55%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CORT |
Sell
All
|
17.92% |
Assets Rebalanced
None
2024-11-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
4.96% |
11.71% |
2024-11-05 |
|
CHRS
Coherus BioSciences, Inc.
|
Buy |
6.45% |
34.15% |
2024-11-08 |
|
ITGR
Integer Holdings Corporation
|
Buy |
4.34% |
-0.64% |
2024-11-11 |
The percentage of cash held in the portfolio is:
84.26%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ATEC |
Sell
All
|
30.06% |
Assets Rebalanced
None